Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PTGX Stock Forecast 2026-2027
$135.46
Current Price
$8.44B
Market Cap
Buy 12
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to PTGX Price Targets
+7.0%
To High Target of $145.00
-12.9%
To Median Target of $118.00
-26.2%
To Low Target of $100.00
PTGX Price Momentum
+3.1%
1 Week Change
+21.6%
1 Month Change
+140.0%
1 Year Change
+55.1%
Year-to-Date Change
-4.0%
From 52W High of $141.10
+168.3%
From 52W Low of $50.49
📊 TOP ANALYST CALLS
Did PTGX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Protagonist is one of their latest high-conviction picks.
Latest PTGX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, PTGX has a bullish consensus with a median price target of $118.00 (ranging from $100.00 to $145.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $135.46, the median forecast implies a -12.9% downside. This outlook is supported by 12 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Srikripa Devarakonda at Truist Securities, projecting a 7.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PTGX Analyst Ratings
12
Buy
1
Hold
0
Sell
PTGX Price Target Range
Low
$100.00
Average
$118.00
High
$145.00
Current: $135.46
Latest PTGX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PTGX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 7, 2026 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $145.00 |
| May 6, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| May 6, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Apr 15, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Apr 7, 2026 | Clear Street | Buy | Maintains | $N/A | |
| Mar 19, 2026 | Leerink Partners | Outperform | Maintains | $N/A | |
| Mar 19, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| Mar 19, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Mar 19, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Mar 3, 2026 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Feb 26, 2026 | TD Cowen | Buy | Maintains | $N/A | |
| Feb 26, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Feb 26, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| Feb 2, 2026 | Jefferies | Buy | Maintains | $N/A | |
| Jan 30, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 5, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Dec 17, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Dec 8, 2025 | Citigroup | Buy | Maintains | $N/A | |
| Nov 10, 2025 | Citigroup | Buy | Maintains | $N/A | |
| Nov 7, 2025 | JP Morgan | Overweight | Maintains | $N/A |
Protagonist Therapeutics Inc. (PTGX) Competitors
The following stocks are similar to Protagonist based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Protagonist Therapeutics Inc. (PTGX) Financial Data
Protagonist Therapeutics Inc. has a market capitalization of $8.44B with a P/E ratio of 139.5x. The company generates $74.06M in trailing twelve-month revenue with a -154.9% profit margin.
Revenue growth is +99.0% quarter-over-quarter, while maintaining an operating margin of -6.5% and return on equity of -17.1%.
Valuation Metrics
Market Cap
$8.44B
Enterprise Value
$7.91B
P/E Ratio
139.5x
PEG Ratio
-1.1x
Price/Sales
110.2x
Growth & Margins
Revenue Growth (YoY)
+99.0%
Gross Margin
N/A
Operating Margin
-6.5%
Net Margin
-154.9%
EPS Growth
+99.0%
Financial Health
Cash/Price Ratio
+6.3%
Current Ratio
17.8x
Debt/Equity
1.5x
ROE
-17.1%
ROA
-12.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Protagonist Therapeutics Inc. (PTGX) Business Model
About Protagonist Therapeutics Inc.
What They Do
Develops peptide-based therapeutics for unmet medical needs.
Business Model
The company operates as a clinical-stage biopharmaceutical entity, generating revenue primarily through the development of its proprietary peptide-based therapeutics targeting various medical conditions. It engages in collaborations with established pharmaceutical companies, such as Johnson & Johnson and Takeda, which can provide financial support and shared expertise in advancing its drug candidates through clinical trials.
Additional Information
Protagonist Therapeutics has a diverse pipeline with several candidates in different stages of development, including phase 3 trials for polycythemia vera and plaque psoriasis. Founded in 2006 and based in Newark, California, the company is focused on pioneering oral alternatives to injectable therapies, addressing critical areas like hematology, inflammation, and immunology, which may lead to significant improvements in patient care.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
128
CEO
Dr. Dinesh V. Patel Ph.D.
Country
United States
IPO Year
2016
Website
www.protagonist-inc.comProtagonist Therapeutics Inc. (PTGX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Best Momentum Stocks to Buy for July 13th
SNDK, PTGX and LION made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13th, 2026.
Jul 13, 2026
By Zacks Equity Research
Zacks #1 Rank Additions
Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?
Protagonist Therapeutics (PTGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Jul 08, 2026
By Zacks Equity Research
Tale of the Tape
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Jul 08, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
New Strong Buy Stocks for July 13th
3 days ago
Quick Summary
FOX, LION, EDRY, PTGX, and SPH were added to the Zacks Rank #1 (Strong Buy) List on July 13, 2026.
Why It Matters
The addition of FOX, LION, EDRY, PTGX, and SPH to the Zacks Rank #1 (Strong Buy) indicates strong potential for price appreciation, signaling favorable investment opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Best Momentum Stocks to Buy for July 13th
3 days ago
Quick Summary
SNDK, PTGX, and LION are rated Zacks Rank #1 (Strong Buy) as of July 13, 2026, indicating positive momentum for these stocks.
Why It Matters
SNDK, PTGX, and LION's inclusion in the Zacks Rank #1 list signals strong bullish sentiment, indicating potential for price appreciation and attractive investment opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Protagonist Therapeutics (PTGX) shares rose on high trading volume, but recent earnings estimate revisions do not indicate continued strength.
Why It Matters
The surge in Protagonist Therapeutics' share price indicates heightened investor interest, but negative earnings estimate revisions signal potential future weakness, raising caution for prospective investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
New Strong Buy Stocks for July 9th
7 days ago
Quick Summary
PTGX, DHX, COOK, XYZ, and ARLP were added to the Zacks Rank #1 (Strong Buy) List on July 9, 2026.
Why It Matters
Zacks Rank #1 indicates strong growth potential for PTGX, DHX, COOK, XYZ, and ARLP, signaling favorable investment opportunities that may lead to price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Protagonist shares increase as rusfertide approaches an FDA decision, and Icotyde includes milestone payments, royalties, and a strengthened pipeline.
Why It Matters
Protagonist's rising shares indicate positive market sentiment ahead of the FDA decision on rusfertide, signaling potential revenue growth from Icotyde's milestone payments and expanding pipeline.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Protagonist Therapeutics (Nasdaq:PTGX) granted inducement awards to three new employees on June 30, 2026, under its Amended and Restated Inducement Plan.
Why It Matters
Inducement awards can signal company growth and expansion, potentially leading to increased productivity and innovation, which may positively impact stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About PTGX Stock
What is Protagonist Therapeutics Inc.'s (PTGX) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Protagonist Therapeutics Inc. (PTGX) has a median price target of $118.00. The highest price target is $145.00 and the lowest is $100.00.
Is PTGX stock a good investment in 2027?
According to current analyst ratings, PTGX has 12 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $135.46. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PTGX stock?
Wall Street analysts predict PTGX stock could reach $118.00 in the next 12 months. This represents a -12.9% decrease from the current price of $135.46. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Protagonist Therapeutics Inc.'s business model?
The company operates as a clinical-stage biopharmaceutical entity, generating revenue primarily through the development of its proprietary peptide-based therapeutics targeting various medical conditions. It engages in collaborations with established pharmaceutical companies, such as Johnson & Johnson and Takeda, which can provide financial support and shared expertise in advancing its drug candidates through clinical trials.
What is the highest forecasted price for PTGX Protagonist Therapeutics Inc.?
The highest price target for PTGX is $145.00 from Srikripa Devarakonda at Truist Securities, which represents a 7.0% increase from the current price of $135.46.
What is the lowest forecasted price for PTGX Protagonist Therapeutics Inc.?
The lowest price target for PTGX is $100.00 from at , which represents a -26.2% decrease from the current price of $135.46.
What is the overall PTGX consensus from analysts for Protagonist Therapeutics Inc.?
The overall analyst consensus for PTGX is bullish. Out of 3 Wall Street analysts, 12 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $118.00.
How accurate are PTGX stock price projections?
Stock price projections, including those for Protagonist Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 1:10 PM UTC